July 3, 2007 - Ivivi Technologies Inc., a non-invasive, electrotherapeutic technology developer, announced that it has completed enrollment of 30 patients participating in a double-blind, randomized, placebo-controlled clinical trial utilizing its pulsed electromagnetic field (PEMF) technology to treat patients with ischemic cardiomyopathies conducted at The Cleveland Clinic Florida.
The trial is designed for cardiac patients who are not candidates for surgical intervention such as angioplasty, stenting or cardiac bypass surgery but will analyze the use of PEMF technology over five months on patients with ischemic cardiomyopathy. The primary objective is the improvement in regional myocardial perfusion and function as seen with a 64-slice CT scan. The secondary objective is patient improvement for angina and exercise tolerance. Data analysis and results is expected to be available by the end of 2007.
Doctors anticipate that the non-invasive application of PEMF technology may improve cardiac circulation by increasing blood flow and stimulating the growth of new blood vessels, potentially reducing the need for many invasive cardiac procedures.
For more information: www.ivivitechnologies.com
May 20, 2024 
